Israeli cancer immunotherapy firm Compugen said on Monday it had positive initial results from an ongoing early-stage study of its COM701 therapy in patients with advanced solid tumours who have exhausted all standard treatments.
from Reuters: Science News https://ift.tt/2VEpK9k
0 comments:
Post a Comment